In a patient with hepatic impairment and CKD, which method would help determine a safe dosing regimen for a drug with both hepatic and renal clearance?

• A. PK model incorporating both hepatic and renal clearance and simulation to determine safe dose/interval
• B. Rely on trial and error
• C. Double the standard dose
• D. Increase frequency arbitrarily

Answer: (B)

When a drug is cleared by both the liver and the kidneys and both functions are impaired, you need a dosing approach that reflects how each clearance pathway contributes and how impairment shifts overall exposure. A pharmacokinetic model that includes both hepatic and renal clearance allows you to predict how changes in dose and dosing interval will alter key exposure metrics (like AUC, Cmax, and troughs) in the patient population with combined organ dysfunction. By running simulations across plausible regimens, you can identify a dose and interval that achieve target exposure without pushing levels too high and risking toxicity.

This approach is superior because it directly accounts for how reduced metabolism and reduced excretion interact, possibly altering distribution and protein binding as well. It also lets you tailor regimens to individual patient characteristics and perform sensitivity analyses, which is much safer and more efficient than trying regimens by trial and error. Simply doubling the dose or increasing frequency arbitrarily ignores how clearance is altered and can lead to excessive exposure or unstable drug levels.